Qol Holdings Co., Ltd.
3034・Prime Market・Retail Trade
BPO Business
Group's second-largest earnings pillar, developing healthcare-related BPO services
| Period | Current | Previous | Change |
|---|---|---|---|
| Sales (full year, FY2026 (ending March 2026)) | ¥14,300 million | ¥13,603 million | ↑ |
| Segment profit (full year, FY2026 (ending March 2026)) | ¥1,898 million | ¥1,706 million | ↑ |
| Sales growth rate (full year, FY2026 (ending March 2026)) | up 5.1% | — | ↑ |
| Segment profit growth rate (full year, FY2026 (ending March 2026)) | up 11.3% | — | ↑ |
| Goodwill amortization (full year, FY2026 (ending March 2026)) | ¥305 million | ¥269 million | ↑ |
| Goodwill balance (end of FY2026 (ending March 2026)) | ¥1,326 million | ¥1,155 million | ↑ |
| Segment assets (end of FY2026 (ending March 2026)) | ¥8,302 million | ¥8,568 million | ↓ |
Business Details
Consolidated subsidiaries centered on Apoplus Station Co., Ltd. operate four businesses: CSO Business (MR Dispatch), CRO Business (contract development services for pharmaceuticals and food), Referral Staffing Business (staffing services for pharmacists, doctors, nurses, etc.), and Publishing-related Business (conventions, compliance services, and materials production). The main customers are pharmaceutical companies and medical institutions, addressing diverse outsourcing needs in medical settings. This segment accounts for approximately 4.9% of the Group's total sales.
Recent Overview
CSO and Publishing-related businesses drove 5.1% sales growth, with improved profit margins delivering 11.3% operating profit growth
For the full year of FY2026 (ending March 2026), sales were ¥14,300 million (up 5.1% year on year) and segment profit was ¥1,898 million (up 11.3% year on year), achieving both higher sales and higher profit. In the CSO Business, the number of dispatched personnel expanded due to an increase in the number of companies utilizing dispatched MRs, and profit margins also improved through revisions to dispatch unit prices. In the Publishing-related Business, expansion of clients in the convention and compliance service businesses and profit margin improvement through in-house production contributed to results. In November 2025, Clin Cloud Co., Ltd. was brought into the Group with the aim of strengthening the CRO Business.
Key Products
Growth Drivers
- Expansion of pharmaceutical companies' demand for MR dispatch in the CSO Business, increased dispatch numbers, and improved profit margins through revisions to dispatch unit prices
- Expansion of clients in the convention and compliance service businesses within the Publishing-related Business and improved profit margins through in-house production
- EDC utilization synergies from bringing Clin Cloud Co., Ltd. into the Group in the CRO Business, and development of new customers and contracted service areas
- Increase in successful placements in the Referral Staffing Business following enhanced recruiting in the prior period, and productivity improvement through AI utilization
- Diversification of revenue sources through expansion of new businesses related to spot pharmacist staffing and occupational physicians/occupational health nurses
Risks
- Profit pressure from increased recruitment costs and personnel expenses in the CSO Business
- Increase in fixed costs such as personnel expenses and advertising expenses in the Referral Staffing Business
- Business impact from failure to obtain permits, registrations, designations, or licenses from various prefectures, or from violations or amendments to related laws and regulations
- Risk of rising recruitment costs due to intensifying competition for healthcare-related talent
- Risk of delayed synergy realization following the group acquisition of Clin Cloud Co., Ltd.
Last updated: June 25, 2026